XML 33 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurement - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2013 Novozymes Biopharma DK A/S Sweden Ab Earn Out Payment EUR (€)	Sep. 30, 2013 Novozymes Biopharma DK A/S Sweden Ab Earn Out Payment EUR (€)	Sep. 30, 2013 Bio Flash Partners Limited Liability Company Minimum USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition, contingent payment	€ 1,000,000	€ 1,000,000
Minimum royalty payment			$ 55,000

X

- Definition

Amount of (increase) decrease in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration